JP2011509311A - 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 - Google Patents

治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Download PDF

Info

Publication number
JP2011509311A
JP2011509311A JP2010542394A JP2010542394A JP2011509311A JP 2011509311 A JP2011509311 A JP 2011509311A JP 2010542394 A JP2010542394 A JP 2010542394A JP 2010542394 A JP2010542394 A JP 2010542394A JP 2011509311 A JP2011509311 A JP 2011509311A
Authority
JP
Japan
Prior art keywords
hydrophobic
composition
solution
chain
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010542394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509311A5 (https=
Inventor
ジェラルド エム． カスティロ，
エリジャー エム． ボロティン，
Original Assignee
ファーマイン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマイン コーポレイション filed Critical ファーマイン コーポレイション
Publication of JP2011509311A publication Critical patent/JP2011509311A/ja
Publication of JP2011509311A5 publication Critical patent/JP2011509311A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010542394A 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Withdrawn JP2011509311A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/971,482 US20090176892A1 (en) 2008-01-09 2008-01-09 Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
PCT/US2009/030678 WO2009089506A1 (en) 2008-01-09 2009-01-09 Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013259956A Division JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Publications (2)

Publication Number Publication Date
JP2011509311A true JP2011509311A (ja) 2011-03-24
JP2011509311A5 JP2011509311A5 (https=) 2013-01-31

Family

ID=40845092

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Country Status (4)

Country Link
US (3) US20090176892A1 (https=)
EP (1) EP2240165B1 (https=)
JP (5) JP2011509311A (https=)
WO (1) WO2009089506A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010100781A (ja) * 2008-10-27 2010-05-06 Josho Gakuen 高分子、経上皮吸収促進剤、及び医薬用製剤
KR20170109526A (ko) * 2014-11-03 2017-09-29 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101529318B1 (ko) 2005-12-19 2015-06-16 파마인 코포레이션 치료제를 전달하기 위한 소수성 코어 담체 조성물, 이조성물의 제조 방법 및 그 조성물의 이용 방법
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA2773737C (en) * 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
WO2012051457A1 (en) * 2010-10-14 2012-04-19 Nitto Denko Corporation Nucleic acid delivery compounds
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2018017954A1 (en) * 2016-07-21 2018-01-25 Rutgers, The State University Of New Jersey Antimicrobial cationic systems and methods of use
WO2019110788A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US20190275108A1 (en) * 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
FR3083086A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SG11202005319PA (en) 2017-12-07 2020-07-29 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002194080A (ja) * 2000-12-27 2002-07-10 Mitsui Chemicals Inc 重合体及びその製造方法
US6576254B1 (en) * 1998-05-23 2003-06-10 University Of Strathclyde Polyamino acid vesicles
WO2005115492A1 (en) * 2004-05-25 2005-12-08 Biointeractions Ltd Absorbable biocompatible materials
US20070141145A1 (en) * 2005-12-19 2007-06-21 Pharmaln Ltd. Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
DK0636028T3 (da) * 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
ES2199226T3 (es) * 1992-09-04 2004-02-16 The General Hospital Corporation Polimeros biocompatibles que contienen mitades diagnosticas o terapeuticas.
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
FI955320A7 (fi) * 1994-03-07 1995-11-24 Univ Michigan Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
JPH11507697A (ja) * 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
EP0856026A1 (en) * 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
NZ502358A (en) * 1997-07-18 2002-11-26 Infimed Therapeutics Inc Hydrogel composition comprising a biologically active substance combined with a macromer
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
ATE445006T1 (de) * 1998-08-10 2009-10-15 Us Gov Health & Human Serv Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
CA2340118C (en) * 1998-08-12 2009-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
CA2358463A1 (en) * 1999-01-08 2000-07-13 Virginia Commonwealth University Polymeric delivery agents and delivery agent compounds
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
EP1258401B1 (en) * 2000-02-22 2017-10-11 Daicel Chemical Industries, Ltd. Airbag gas generator
MXPA02009031A (es) * 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
ATE397938T1 (de) * 2000-05-19 2008-07-15 Amylin Pharmaceuticals Inc Behandlung des akuten koronaren syndroms mit glp- 1
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
EP1301213B1 (en) * 2000-07-21 2017-01-18 ReVance Therapeutics, Inc. Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1351984A2 (en) * 2000-12-13 2003-10-15 Eli Lilly And Company Amidated glucagon-like peptide-1
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
US7144863B2 (en) * 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
AU2002316811A1 (en) * 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
CA2458371A1 (en) * 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
US20040235726A1 (en) * 2001-10-01 2004-11-25 Jakubowski Joseph Anthony Glucagon-like peptides (glp-1) and treatment of respiratory distress
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
IL161446A0 (en) * 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
CN1332711C (zh) * 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072143A1 (en) * 2002-02-27 2003-09-04 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6705987B2 (en) * 2002-04-17 2004-03-16 Endocare, Inc. Penile seal and constriction ring
EP1525219B1 (en) * 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
EP1530491A1 (en) 2002-08-13 2005-05-18 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
JP2006501820A (ja) 2002-09-06 2006-01-19 バイエル・フアーマシユーチカルズ・コーポレーシヨン 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
DE602004015755D1 (de) * 2003-03-31 2008-09-25 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
ATE541582T1 (de) * 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
EP2292253A3 (en) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7521527B2 (en) * 2003-12-16 2009-04-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. GLP-1 pharmaceutical compositions
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
CA2558676C (en) * 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
FR2867679B1 (fr) * 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
BRPI0510093B8 (pt) * 2004-04-20 2022-12-27 Dendritic Nanotechnologies Inc polímeros dendríticos
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
BRPI0513508B1 (pt) * 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
KR100675834B1 (ko) * 2004-10-28 2007-01-29 한국전자통신연구원 루프백 형 파장분할다중방식의 수동형 광 네트워크
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US20100041612A1 (en) 2005-09-08 2010-02-18 Martin Beinborn Fragments of the Glucagon-Like Peptide-1 and Uses Thereof
EP1931397B1 (en) * 2005-10-05 2009-04-08 SCA Hygiene Products AB Absorbent article comprising hydrophilic and hydrophobic regions
AU2006308511B2 (en) 2005-10-25 2013-06-13 Starpharma Pty Limited Macromolecular compounds having controlled stoichiometry
ES2586236T3 (es) 2005-11-04 2016-10-13 Glaxosmithkline Llc Procedimientos para administrar agentes hipoglucémicos
CN104524596B (zh) 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576254B1 (en) * 1998-05-23 2003-06-10 University Of Strathclyde Polyamino acid vesicles
JP2002194080A (ja) * 2000-12-27 2002-07-10 Mitsui Chemicals Inc 重合体及びその製造方法
WO2005115492A1 (en) * 2004-05-25 2005-12-08 Biointeractions Ltd Absorbable biocompatible materials
US20070141145A1 (en) * 2005-12-19 2007-06-21 Pharmaln Ltd. Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010100781A (ja) * 2008-10-27 2010-05-06 Josho Gakuen 高分子、経上皮吸収促進剤、及び医薬用製剤
KR20170109526A (ko) * 2014-11-03 2017-09-29 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법
JP2018505230A (ja) * 2014-11-03 2018-02-22 ファーマイン コーポレイション 優れたペプチドおよびタンパク質結合特性を備えたグラフトコポリマー賦形剤の生成の方法
KR102369119B1 (ko) 2014-11-03 2022-02-28 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법

Also Published As

Publication number Publication date
EP2240165B1 (en) 2019-03-06
JP2017190357A (ja) 2017-10-19
JP2014156486A (ja) 2014-08-28
EP2240165A1 (en) 2010-10-20
WO2009089506A1 (en) 2009-07-16
US20100234279A1 (en) 2010-09-16
JP5878912B2 (ja) 2016-03-08
US9562111B2 (en) 2017-02-07
JP2016153429A (ja) 2016-08-25
US20090176892A1 (en) 2009-07-09
US20150284476A1 (en) 2015-10-08
US8999930B2 (en) 2015-04-07
EP2240165A4 (en) 2013-05-22
JP6244400B2 (ja) 2017-12-06
JP2014058562A (ja) 2014-04-03
JP6342556B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
JP6342556B2 (ja) 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
AU2015242970B2 (en) Glycopolysialylation of non-blood coagulation proteins
KR101759300B1 (ko) 비혈액 응고 단백질의 글리코폴리시알화
CN104906594B (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
EP3449946A2 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2022058911A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
Tuesca et al. Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels
Salmaso et al. Nanotechnologies in protein delivery
EP2389198A1 (en) Site-specific monoconjugated insulinotropic glp-1 peptides
US20060286657A1 (en) Novel bioconjugation reactions for acylating polyethylene glycol reagents
LUKYANOV et al. PEGylated dextran as long-circulating pharmaceutical
HARTNER et al. ANATOLY N. LUKYANOV, RISHIKESH M. SAWANT
Orlando Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES): HESylation-a new technology for polymer conjugation to biologically active molecules
HK1230072A1 (en) Conjugate comprising erythropoietin and a branched polymer structure
CN106163541A (zh) 包含促红细胞生成素和支化聚合物结构的缀合物
HK1171667B (en) Glycopolysialylation of proteins other than blood coagulation proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140304